- Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent E - PharmiWeb.com
- resTORbio Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Global Phase 3 Program for RTB101 - Nasdaq
- Bristol-Myers Squibb-Pfizer Alliance reports data from AUGUSTUS trial - Drug Development Technology
- How the surgical setting contributes to the opioid crisis - Endpoints News
- The impact of pharmaceutical rebates on patients' drug expenditures - CMAJ
Archives by date
You are browsing the site archives by date.
October 29, 2015